| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2589 | 2018 |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237, 2018 | 2366* | 2018 |
| Prophylactic cranial irradiation in extensive small-cell lung cancer B Slotman, C Faivre-Finn, G Kramer, E Rankin, M Snee, M Hatton, ... New England Journal of Medicine 357 (7), 664-672, 2007 | 1314 | 2007 |
| ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) A Brunelli, A Charloux, CT Bolliger, G Rocco, JP Sculier, G Varela, ... European Respiratory Journal 34 (1), 17-41, 2009 | 1043* | 2009 |
| Imaging biomarker roadmap for cancer studies JPB O'connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1021 | 2017 |
| Small-cell lung cancer CM Rudin, E Brambilla, C Faivre-Finn, J Sage Nature Reviews Disease Primers 7 (1), 3, 2021 | 756 | 2021 |
| Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection … P Mulvenna, M Nankivell, R Barton, C Faivre-Finn, P Wilson, E McColl, ... The Lancet 388 (10055), 2004-2014, 2016 | 678 | 2016 |
| Guidelines on the radical management of patients with lung cancer E Lim, D Baldwin, M Beckles, J Duffy, J Entwisle, C Faivre-Finn, K Kerr, ... Thorax 65 (Suppl 3), iii1-iii27, 2010 | 666 | 2010 |
| Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ... Journal of Clinical Oncology 40 (12), 1301, 2022 | 585 | 2022 |
| Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial BJ Slotman, H van Tinteren, JO Praag, JL Knegjens, SY El Sharouni, ... The Lancet 385 (9962), 36-42, 2015 | 585 | 2015 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 534 | 2014 |
| Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial C Faivre-Finn, M Snee, L Ashcroft, W Appel, F Barlesi, A Bhatnagar, ... The Lancet Oncology 18 (8), 1116-1125, 2017 | 495 | 2017 |
| European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer D De Ruysscher, C Faivre-Finn, U Nestle, CW Hurkmans, C Le Péchoux, ... Journal of clinical oncology 28 (36), 5301-5310, 2010 | 490* | 2010 |
| Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N Girard, E Ruffini, A Marx, C Faivre-Finn, S Peters Annals of Oncology 26, v40-v55, 2015 | 441 | 2015 |
| Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and … C Le Péchoux, A Dunant, S Senan, A Wolfson, E Quoix, C Faivre-Finn, ... The lancet oncology 10 (5), 467-474, 2009 | 430 | 2009 |
| Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... Journal of Thoracic Oncology 15 (2), 288-293, 2020 | 402 | 2020 |
| 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ... Annals of Oncology 26 (8), 1573-1588, 2015 | 402 | 2015 |
| Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, ... Journal of Thoracic Oncology 16 (5), 860-867, 2021 | 388 | 2021 |
| Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer E Touboul, L Buffat, Y Belkacémi, JP Lefranc, S Uzan, P Lhuillier, C Faivre, ... Int J Radiat Oncol Biol Phys 43 (1), 25-38, 1999 | 366 | 1999 |
| Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ... Annals of Oncology 25 (9), 1681-1690, 2014 | 358 | 2014 |
